ADAM18

Across TCGA pan-cancer cohorts, ADAM18 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ADAM18 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher ADAM18 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADAM18 expression acts as an unfavorable survival marker, although some lineages such as SKCM and UCEC show a favorable association.

SCLC, LIHC, and PRAD are the cancer types where ADAM18 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.082	0.702	<.001	24	view →
LIHC	OS	Median	II,III,IV	0.093	0.696	<.001	9	view →
PRAD	DFS	Median	All	0.617	0.886	.015	6	view →
SKCM	DFS	Median	II,III,IV	0.790	0.652	.016	5	view →
UCEC	DFS	Median	All	1.000	0.892	.041	4	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ADAM18–SCLC (OS)

Open the SCLC breakdown →